FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
First FDA-Approved As-Needed Treatment for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women NDA Approval Triggers $60 Million Milestone Payment to Palatin Jun 21, 2019, 17:40 ET CRANBURY, N.J., June 21, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval …
FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection) Read More »